In this nationwide secondary prevention cohort, the risk of NODM differed across individual statins despite comparable cardiovascular outcomes. These findings suggest that the diabetogenic effect of statins may be agent-specific rather than a uniform class effect, highlighting the importance of individualized statin selection balancing metabolic and cardiovascular benefits.